yahoo_financeOriginal article
The Lancet Neurology Publishes Data From Alkermes’ Positive Vibrance-1 Phase 2 Study of Alixorexton in Adults With Narcolepsy Type 1
Phase 2positiveAlixorextonPositive
AI Analysis
Summary
Alkermes announced publication of positive Phase 2 Vibrance-1 study data for Alixorexton in adults with Narcolepsy Type 1 in The Lancet Neurology.
Clinical Trial Data
Phase
Phase 2
Primary Endpoint
Met
Outcome Details
Vibrance-1 Phase 2 study positive data published in The Lancet Neurology
Importance:7/10
Sentiment:
0.70
Phase 2 datanarcolepsyAlixorextonpositive trialpublication
Related Companies
Read the original article
Published by yahoo_finance on August 24, 2026 10:30 PM